Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biogen Inc (NASDAQ:BIIB)

291.13
Delayed Data
As of Feb 27
 +6.00 / +2.10%
Today’s Change
205.42
Today|||52-Week Range
307.33
+11.46%
Year-to-Date
After Starboard Agitation, Perrigo Sells MS Drug Royalties for Up to $2.85B
Feb 27 / TheStreet.com - Paid Partner Content
Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?
Feb 21 / Zacks.com - Paid Partner Content
Better Buy: Biogen Inc. vs. Gilead Sciences Inc.
Feb 27 / MotleyFool.com - Paid Partner Content
Did Biogen Inc. Shoot Itself in the Foot?
Feb 21 / MotleyFool.com - Paid Partner Content
Ring the Register With These Upcoming Spinoffs
Feb 24 / TheStreet.com - Paid Partner Content
3 Top Drug Stocks That Can Be Purchased on the Cheap This Winter
Feb 20 / MotleyFool.com - Paid Partner Content
Here's Why Celgene's Latest Drug Is So Exciting
Feb 23 / MotleyFool.com - Paid Partner Content
Could Celgene Have Another Billion-Dollar Blockbuster on Its Hands?
Feb 19 / MotleyFool.com - Paid Partner Content
Andreas Halvorsen Buys Maker of First-in-Class Cancer Treatments, Calithera Bioscienc...
Feb 22 / GuruFocus News - Paid Partner Content
Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback
Feb 16 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close285.13
Today’s open285.39
Day’s range284.27 - 291.25
Volume1,295,089
Average volume (3 months)1,776,964
Market cap$62.9B
Dividend yield--
Data as of 02/27/2017

Growth & Valuation

Earnings growth (last year)+10.32%
Earnings growth (this year)+3.79%
Earnings growth (next 5 years)+8.72%
Revenue growth (last year)+9.37%
P/E ratio17.2
Price/Sales6.09
Price/Book5.18

Competitors

 Today’s
change
Today’s
% change
GILDGilead Sciences+0.56+0.80%
ILMNIllumina Inc+6.82+4.26%
BIVVBioverativ Inc-0.37-0.73%
TECHBio-Techne Corp+0.85+0.80%
Data as of 02/27/2017

Financials

Next reporting dateApril 27, 2017
EPS forecast (this quarter)$5.00
Annual revenue (last year)$10.2B
Annual profit (last year)$3.7B
Net profit margin36.32%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Michel Vounatsos
Chief Financial Officer &
Executive Vice President
Paul J. Clancy
Corporate headquarters
Cambridge, Massachusetts

Forecasts


Search for Jobs